Lynda Chin

Chin was a member of the Dana–Farber Cancer Institute's Department of Medical Oncology from 1999 until joining the University of Texas MD Anderson Cancer Center in 2011.^[6]

She was a professor of Dermatology at the Harvard Medical School.^[6]

Chin was a Senior Associate Member of the Broad Institute, where she became the principal researcher of the Genome Data Analysis Center in The Cancer Genome Atlas (TCGA).^[6] Chin was then elected scientific director of the Belfer Institute for Applied Cancer Science at the Dana–Farber Cancer Institute. Chin was a co-leader of the Dana-Farber/Harvard Cancer Center's Melanoma Program and the Specialized Programs of Research Excellence (SPORE) grant for skin research.^[6]

In 2002, Chin co-founded a cancer biotechnology company called AVEO Pharmaceuticals. 5 years later, Chin founded Metamark Genetics, a cancer diagnostic company dedicated to the development of prognostic and predictive cancer tests.^[6]

Chin joined the University of Texas MD Anderson Cancer Center in 2011 as chair of first-ever Department of Genomic Medicine and scientific director of the Institute for Applied Cancer Science. She assists the scientific steering committee of the International Cancer Genome Consortium.^[6]

In 2012, Chin was involved in controversial grant award by the Cancer Prevention and Research Institute of Texas (CPRIT). A Houston Chronicle investigation suggests that CPRIT her application for the approximately $18 million grant had been handled in a hasty manner designed to circumvent its own scientific reviewers.^[7]

She is a recipient of the 2014 Lila and Murray Gruber Memorial Cancer Research Award.

Chin met her husband, Ronald A. DePinho, as a medical student at Albert Einstein College of Medicine in New York City. Chin and her husband have three children together.^[8]